COVID-19 and diabetes mellitus: how one pandemic worsens the other

Rev Endocr Metab Disord. 2020 Dec;21(4):451-463. doi: 10.1007/s11154-020-09573-6.

Abstract

In light of the most challenging public health crisis of modern history, COVID-19 mortality continues to rise at an alarming rate. Patients with co-morbidities such as hypertension, cardiovascular disease, and diabetes mellitus (DM) seem to be more prone to severe symptoms and appear to have a higher mortality rate. In this review, we elucidate suggested mechanisms underlying the increased susceptibility of patients with diabetes to infection with SARS-CoV-2 with a more severe COVID-19 disease. The worsened prognosis of COVID-19 patients with DM can be attributed to a facilitated viral uptake assisted by the host's receptor angiotensin-converting enzyme 2 (ACE2). It can also be associated with a higher basal level of pro-inflammatory cytokines present in patients with diabetes, which enables a hyperinflammatory "cytokine storm" in response to the virus. This review also suggests a link between elevated levels of IL-6 and AMPK/mTOR signaling pathway and their role in exacerbating diabetes-induced complications and insulin resistance. If further studied, these findings could help identify novel therapeutic intervention strategies for patients with diabetes comorbid with COVID-19.

Keywords: Adenosine monophosphate kinase (AMPK); Angiotensin-converting enzyme 2; COVID-19; Cytokine storm; Diabetes mellitus; Mechanistic target of Rapamycin (mTOR).

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • COVID-19
  • Comorbidity*
  • Coronavirus Infections / epidemiology
  • Coronavirus Infections / immunology*
  • Diabetes Mellitus / epidemiology
  • Diabetes Mellitus / immunology*
  • Disease Susceptibility / epidemiology
  • Disease Susceptibility / immunology*
  • Humans
  • Pandemics*
  • Pneumonia, Viral / epidemiology
  • Pneumonia, Viral / immunology*